RxDoctor Payments Data

Terry Love, DO

Family Medicine · Ottawa, ILNPI 1124034459

Payments from drug & device makers

$3,415in general payments, 2019–2025

Across 217 payments — averaging $15.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$856
  • AstraZeneca$813
  • Novo Nordisk$331
  • Novartis$219
  • Astellas Pharma US Inc$191
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$161
  • plus $845 from 18 others

What the payments were for

  • Food & beverage$3,23695%
  • Education$1795%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,415 in reported general payments places this provider in the 85th percentile of 4,116 family medicine providers in Illinois.

See all family medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$73,777
Medicare patients
178
Services billed
940

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban59$46,597
OzempicSemaglutide45$46,042
FarxigaDapagliflozin Propanediol27$26,726
Breztri AerosphereBudesonide/Glycopyr/Formoterol31$23,916
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog20$23,724
JardianceEmpagliflozin28$20,883
XareltoRivaroxaban12$14,569
JanuviaSitagliptin Phosphate11$13,747
TrulicityDulaglutide14$11,730
MyrbetriqMirabegron13$8,128
SymbicortBudesonide/Formoterol Fumarate26$6,966
Combivent RespimatIpratropium/Albuterol Sulfate11$6,235
Lantus SolostarInsulin Glargine,hum.Rec.Anlog29$5,238
Albuterol Sulfate HfaAlbuterol Sulfate184$4,212
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen141$4,131

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$813$57,60784 claims
PfizerEliquis$157$46,59759 claims
Novo NordiskOzempic$331$46,04245 claims
Johnson & JohnsonXarelto$46$14,56912 claims
MerckJanuvia$12$13,74711 claims
Lilly USA, LLCTrulicity$38$11,73014 claims
Astellas Pharma US IncMyrbetriq$191$8,12813 claims
AbbVieSynthroid$856$93318 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,116 family medicine providers in Illinois.

Other family medicine in Ottawa

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →